Skip to content
Filgotinib
Jyseleca (filgotinib) is a small molecule pharmaceutical. Filgotinib was first approved as Jyseleca on 2020-09-24. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK1. In addition, it is known to target tyrosine-protein kinase JAK3, non-receptor tyrosine-protein kinase TYK2, and tyrosine-protein kinase JAK2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA45: Filgotinib
HCPCS
No data
Clinical
Clinical Trials
48 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.92752218
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Psoriatic arthritisD015535EFO_0003778L40.5—32——5
Ankylosing spondylitisD013167EFO_0003898M45—22——4
Crohn diseaseD003424EFO_0000384K50—22——4
Ulcerative colitisD003093EFO_0000729K51——3——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Membranous glomerulonephritisD015433EFO_0004254N03.2—1———1
Inflammatory bowel diseasesD015212EFO_0003767—1———1
Cutaneous lupus erythematosusD008178EFO_0003834L93.1—1———1
Sjogren's syndromeD012859EFO_0000699M35.0—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—7————7
Renal insufficiencyD051437HP_0000083N191————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFILGOTINIB
INNfilgotinib
Description
Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA). It was developed by the Belgian-Dutch biotech company Galapagos NV.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Identifiers
PDB—
CAS-ID1206161-97-8
RxCUI—
ChEMBL IDCHEMBL3301607
ChEBI ID—
PubChem CID49831257
DrugBankDB14845
UNII ID3XVL385Q0M (ChemIDplus, GSRS)
Target
Agency Approved
JAK1
JAK1
Organism
Homo sapiens
Gene name
JAK1
Gene synonyms
JAK1A, JAK1B
NCBI Gene ID
3716
Protein name
tyrosine-protein kinase JAK1
Protein synonyms
JAK-1, Janus kinase 1
Uniprot ID
Q9UD26
Mouse ortholog
Jak1 (16451)
tyrosine-protein kinase JAK1 (P52332)
Alternate
JAK3
JAK3
TYK2
TYK2
JAK2
JAK2
Organism
Homo sapiens
Gene name
JAK3
Gene synonyms
NCBI Gene ID
3718
Protein name
tyrosine-protein kinase JAK3
Protein synonyms
JAK-3, Janus kinase 3, Janus kinase 3 (a protein tyrosine kinase, leukocyte), L-JAK, Leukocyte janus kinase
Uniprot ID
Q9Y6S2
Mouse ortholog
Jak3 (16453)
tyrosine-protein kinase JAK3 (Q62137)
Variants
Clinical Variant
No data
Financial
Jyseleca - Galapagos
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 930 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
18 adverse events reported
View more details